Indegene and DrugLogic announce partnership
Indegene® and DrugLogic® to offer Full Lifecycle Drug Monitoring (FLDM) for insightful analysis of drug behavior, interactions, and safety
NEW YORK, Dec. 16, 2013 /PRNewswire-iReach/ -- Indegene (www.indegene.com) and DrugLogic (www.druglogic.com) announced a joint offering for pharmaceutical companies and healthcare organizations that would combine the extensive medical expertise of Indegene with the sophisticated Big-Data analysis capabilities of DrugLogic's Qscan®. This knowledge and expertise-based offering combines sophisticated evidence-based statistical results, with experience-based physician monitoring, to help decipher a drug's clinical behavior and detect signals related to its safety and interactions with other factors.
Media Contact:
Ann-Marie Craggan, Indegene Inc., +1 732.750.2901, ann-marie.craggan@indegene.com
Steve Wordham, Druglogic, Inc, +1 800.393.1313
RELATED LINKS
http://www.indegene.com
http://www.druglogic.com